KLK4 and Familial prostate cancer: In conclusion, we propose that KLK1, KLK2, KLK3 KLK4, KLK8, KLK9, and KLK14, which are differentially expressed in prostate cancer, could be used as promising biomarkers of prostate cancer progression.